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ABSTRACT
CYNTHIA D. HANSON Evaluation of the Effect of Low Level 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) Exposure on Cell Mediated Immunity.
(Under the direction of RALPH J. SMIALOWICZ)
The immunotoxicity of TCDD in the mouse has been well documented.
To date, the most sensitive endpoint of TCDD-induced immunotoxicity in
mice is that reported by Clark et al.(Proc.Soc.Exp.Biol.Med. 168:290,
1981) who found that TCDD suppressed the murine cytotoxic T lymphocyte
(CTL) response at levels as low as 4ng/kg. However, these data have
not been corroborated, as other laboratories have been unable to detect
immunosuppression by TCDD at such low levels.  In this study, we
evaluated the effect of TCDD on the in vivo and in vitro generated CTL
response to P-815 mastocytoma cells in adult C57BL/6J female mice via a
51cr release assay. Mice were given weekly intraperitoneal injections
of TCDD or vehicle for four weeks at doses ranging from 0.01 to 3.00
ug/kg/week. No statistically significant suppression of the in vivo or
in vitro CTL response was detected at any dose. As expected,
significant increases in liver weights and decreases in thymus weights
were observed at TCDD doses of 1.0 and 3.0 ug/kg/week. Likewise,
suppression of the antibody plaque-forming cell response to sheep
erythrocytes was suppressed at doses of 1.0 and 3.0 pg/kg/week TCDD.
Though expected humoral immunosuppression and organ effects were
observed, our data do not support suppression of murine CTL responses
at the TCDD doses employed in this study.
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I. INTRODUCTION - TCDD
2,3,7,8 Tetrachlorodibenxo-p-dioxin (referred to herein as TCDD)
has been called the most toxic compound known to man. Despite
inconclusive data in humans, TCDD invariably results in alteration of
the gamut of biological processes in laboratory animals. This report
presents a review of the literature on TCDD and evaluates results of
the effect of TCDD on cell mediated immunity.
Dioxin (specifically dibenzodioxin) is a general name for a family
of compounds. The name is indicative of the basic structure - two
benzene rings bridged by two oxygen molecules. The molecule may be
chlorinated (or otherwise halogenated) at any of eight available sites
to form a chlorinated dioxin. The volatility and solubility are
inversely proportional to the degree of chlorination (Skene et al.,
1989); the biological activity of the molecule is also influenced by
chlorination. Maximum activity requires that no fewer than three and
preferably four of the 2,3,7,8 positions be chlorinated. Seventy-five
possible congeners exist, of which the 2,3,7,8 tetrachlorodibenzo-p-
dioxin is the most biologically active and the most intensely studied.
Except in small amounts for research purposes, TCDD is not
manufactured. It is an undesirable by-product formed during the
production of 2,4,5-trichlorophenol (TCP) from 1,2,4,5
tetrachlorobenzene (Homberger et al., 1979). TCP is produced as a
precursor to the herbicide 2,4,5-trichlorophenoxyacetic acid (2,4,5-T)
and to hexachlorophene, a local antiseptic for gram negative bacteria
(Travis and Hattemer-Frey, 1991). Original levels of TCDD
contamination of 2,4,5-T ranged from 1 to 70 ppm; the Council of
Scientific Affairs reported in 1982 that this contamination has been
regulated at less than 0.01 ppm. The infamous herbicide Agent Orange
consisted of a 50:50 mixture of 2,4,5-T and 2,4 dichlorophenoxyacetic
acid (2,4-D) and was contaminated with varying amounts of TCDD. For
decades, mixtures of 2,4-D and 2,4,5-T have been used by homeowners and
farmers for herbicidal purposes (Council on Scientific Affairs, 1982).
Other sources of TCDD include municipal waste and hospital
incinerators, diesel and leaded gasoline burning engine emissions and
paper mill effluent (Skene et al., 1989; Travis and Hattemer-Frey,
1991) . Skene et al. (1989) report that even cigarette smoke and char-
broiled steaks contain low levels of TCDD.
TCDD is ubiquitous throughout the environment.  It has been
measured in all media studied including air, soil, meat, milk, fish,
vegetation and human adipose tissue (Travis and Hattemer-Frey, 1991) .
It is present in virtually all human adipose tissue at levels greater
than 3 ppt (Travis and Hattemer-Frey, 1991) and normal background body
levels in North America range up to 20 ppt (Gough, 1991) . Gough (1991)
notes that men aged 70 years or over, having only ever lived in the
isolated western desert, far from any industry, have adipose tissue
levels of 6 to 7 ppt.
Once in the environment, the bioavailability of TCDD is limited
except through the food chain. It is strongly held by soil, relatively
immobile (Homberger et al., 1979; Skene et al., 1989) and is
transported by wind and rain only so far as its bound particle
(Tschirley, 1986). Since TCDD is lipophilic, it bioaccumulates; the
food chain is thus the major route of uptake (Travis and Hattemer-Frey,
1991) . Dermal absorbtion and inhalation of contaminted particles
account for other routes of exposure especially following industrial or
environmental accident.
TCDD is persistant in the environment when protected from light but
breaks down rapidly in sunlight (Tschirley, 1986) . Photolysis degrades
TCDD in the presence of proton donors, such as oils on the surface of
plant leaves and in moist soils (Council on Scientific Affairs, 1982;
Homberger et al., 1979) . The half life of TCDD in surface soils has
been estimated at 230 days (Council on Scietific Affairs, 1982) and up
to 10 years in areas protected from sunlight (Tschirley, 1986) .
Microorganisms can degrade TCDD, but do so slowly (Tschirley, 1986) .
The toxicity of TCDD (and similar halogenated hydrocarbons or
HAH's) is believed to be mediated through an intracellular protein
receptor, the Ah receptor. This receptor was originally found in
murine liver cells and has been found in almost all tissues studied
(Greenlee et al., 1991). The ubiquitous presence of the Ah receptor
suggests that other mechanisms must influence the extent of responses
mediated by the receptor (Greenlee, 1988; Greenlee et al., 1991) . The
receptor is thus considered necessary but not sufficient for induction
of TCDD toxicity.
Induction results from the initial, reversible binding of TCDD to
the receptor and subsequent transduction of the TCDD-receptor complex
to the nucleus, where it is able to bind specific DNA recognition
elements and alter gene expression (Neal, 1985). Credence is given to
the theory that TCDD toxicity is necessarily mediated through the
receptor due to its solitary lack of covalent binding to genetic
material and negative results in short-term genotoxic bioassays.
There exists little human data to suggest that TCDD exerts severe
adverse effects. TCDD has not been implicated as the cause of even one
human death and most epidemiological studies are inconclusive. Much of
this data is from incidents surrounding the spraying of massive amounts
of herbicide in Vietnam, the ICMESA plant accident in Seveso, Italy,
and the spraying of TCDD contaminated oils in and around Times Beach,
Missouri.
Problems exist in studying human exposure to chemicals. First,
defining the exposed population (Young, 1984) and determining the level
of exposure accurately are extremely difficult. Also, singling out a
compound as wide-spread as TCDD as the direct cause of any effect is
nearly impossible. This problem is exacerbated by the fact that TCDD
rarely occurs in the environment alone, but in conjunction with other
potentially hazardous compounds.
The one consistent outcome of TCDD exposure in humans is the
development of chloracne. This affliction appears two weeks to two
months following exposure and ususally clears 8-26 months after
exposure ceases, the length of affliction depending on the severity of
exposure (Reggiani and Hoffman, 1980). However, there has been no
correlation found between chloracne and alteration in other biological
functions such as increase in serum enzymes and adverse neurological
findings (Homberger et al., 1979; Reggiani and Hoffman, 1980) . No
difference between exposed and non-exposed groups have been observed
including damage to blood cells, kidney function, reproductive outcomes
and liver function, or an increase in chromosome abberations (Reggiani
and Hoffman, 1980; Webb, 1984; Homberger et al., 1979). In terms of
immuno]^ical function, no suppression of cell mediated immunity (Stehr
et al., 1986) or lymphoproliteration to mitogens (Stehr et al., 1986;
Hoffman, 1986) was observed. However, some alteration, though not
statistically significant, has been seen in T lymphocyte subpopulation
ratios (Hoffman et al.,1986; Stehr et al., 1986; Evans et al., 1988).
The U.S. Environmental Protection Agency is currently re-evaluating
its regulation of TCDD. Due to lack of human evidence, the EPA has
conservatively set the current Acceptable Daily Intake (ADI) for TCDD
at 6 fg/kg/day, using a linear, multistage model. This model assumes a
linear relationship exists between outcome and exposure, that adverse
effects begin with exposure to a single molecule and progress, and that
no adverse effects threshold exists (Roberts, 1991b). Using a No
Observable Effect Level (NOEL) and incorporating safety factors, the
Canadian Ministry of the Environment, along with some European
countries, have set their ADI at 10 pg/kg/day, a level 1670 times that
in the U.S.. Recent regulators have been cautiously suggesting that,
if indeed receptor binding is the essential first step in TCDD
toxicity, then this implies that there is a threshold or NOEL below
which no adverse effect occurs and that current EPA regulations are too
strict (Roberts, 1991a, 1991b; Greenlee et al, 1991).
There exists a respectable amount of data in the literature on the
immunotoxic effects of TCDD, including a 1981 paper by Clark et al..
The paper reports the most sensitive endpoint to TCDD mediated
immunotoxicity to date. Here, suppression of the cytotoxic T
lymphocyte (CTL) response was detected at levels as low as 4 ng/kg. The
work has been controversial because not only have the data never been
corraborated but all other reports suggest that TCDD begins exerting
its adverse effects on the immune system at the microgram per kilogram
level or higher. Such a paper may present a problem to the re-
evaluation of TCDD regulation. The purpose of this study was to repeat
Clark's method and re-evaluate the effect of TCDD on the CTL response.
II. IMMUNOLOGY REVIEW
The immune system has evolved as an extremely complex and highly
specific network of organs and cells aimed at ridding its host of
foreign invaders. Since the number and type of possible antigens is
vast, so too is the variability with which this system is able to
attack. Thus, cells of the immune system undergo highly controlled
stages of differentiation before giving rise to such funtionally mature
cells as granulocytes, macrophages and lymphocytes (Dean, 1986) .
Depending on the tissue in which maturation occurs, lymphocytes are
generally classified as T-cells or B-cells; T-cells are thymus
dependent, whereas mammalian B-cells mature in the bone marrow.
Two general types of immunity are recognized - innate and specific.
Innate immunity is nonspecific and requires no prior contact with
foriegn agonist; it lacks specificity for any particular antigen. Such
a non-specific system is useful to any organism as a ready defense
against antigens such as bacteria, viruses and fungi. Non-specific
immunity is most often attributed to both the phagocytic activity of
neutrophils, monocytes and macrophages, (Barrett, 1988) and the
cytolytic activity of natural killer (NK) cells.
Specific immunity refers to that which is developed over the
lifetime of an organism. It is characterized by the development of
immunity for a particular antigen and of immune "memory" for that
antigen in preparation for subsequent exposure. It is antigen specific
and based on either the activities of soluble antibody (humoral
immunity, HI) or cell mediated immunity (CMI). HI and CMI are usually
attributed to B- and T-lymphocytes, respectively, though the two
populations rarely operate independently of one another.
Perturbations of the immune system, by environmental chemicals or
otherwise, may be detrimental to the host. An altered immune system
may be antagonistic to its host, as in the cases of allergy and
autoimmunity. Chemical exposure may render an organism more
susceptible to disease due to alterations in host defense mechanisms
and immunosuppression. The work presented here examines the
immunosuppressive capabilities of TCDD on aquired immunity,
specifically on the cytotoxic T-lymphocytes.
At the core of immunity, is the requirement that host lymphocytes
must recognize antigen. All cells express gene products encoded for by
a group of genetic loci termed the Major Histocompatibility Complex
(MHC). These protein antigens allow for distinction between self and
non-self by acting as cell surface markers. MHC antigens are able to
induce a sub-population of T-cells that are capable of lysing target
cells against which they have been primed, the cytotoxic T lymphocytes
(CTL). There is disagreement surrounding the actual mechanism by which
CTL lyse their target cells. However, it is known that CTL kill
autonomously (Nabholz and MacDonald, 1983), that the lytic event
requires actual contact between CTL and its target (Nabholz and
MacDonald, 1983) and that following delivery of the lethal hit, the CTL
is able to recycle and interact with more targets (Berke, 1991).
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III. IMMUNOTOXICITY LITERATURE REVIEW
The biological and toxicological effects of TCDD are characterized
by diversity. Species differences in site of accumulation, LD50 values
as well as age differences have been well documented. Retention of
tritiated TCDD in the liver accounted for over 40% of the administered
dose in rats, while liver retention in monkeys was less than 10%
(VanMiller et al., 1975). In these monkeys, a large percentage of this
TCDD was found in high lipid content tissues such as skin, muscle and
fat. Gasiewicz et al. (1983) used tritiated TCDD, at a dose of
lOpg/kg, in the C57BL/6J, DBA/2J and B6D2F1/J strains of mice to
determine the liver and adipose tissue as major sites for accumulation.
However, even intraspecies differences exist. The higher percent
adipose tissue in the DBA/2J mice versus the other two strains accounts
for slower excretion rate in these mice.
The lethal dose for 50% of a population (LD50) is a crude, yet
widely used measure of toxicity and is especially applicable when
making comparisons. The LD5Q values for TCDD vary widely among
rodents. Guinea pigs have been shown to be the most sensitive;
hamsters are among the least (see Table 1).
Toxicity induced by TCDD is more profound in the young and unborn
than in adult animals. Thymus, spleen and body weights were depressed
at birth in pups of mothers treated with TCDD during gestation (Faith
and Moore, 1977; Vos and Moore, 1974). Vos and Moore (1974)
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demonstrated the weight response to be dose dependent, the higher dose
of Spg/kg administered to the mother resulting in large numbers of
stillbirths. Ninety-one percent of the mouse pups died by 25 days when
treatment via nursing mothers was continued into the postnatal period.
These effects occured far below lethal doses for adult mice. Pre- and
postnatal treatment exposure of rats has greater and longer lasting
effects than postnatal treatment alone (Faith and Moore, 1977).
Recovery of body weight was never complete in groups treated pre- and
postnatally. Splenic and thymic responses to mitogens (Concanavalin A
and phytohemagglutinin) were always suppressed compared to those
exposed only postnatally and to controls. Also found to be suppressed
in pups of treated mothers were cell-mediated immunity (CMI) (Moore and
Faith, 1976), graft versus host (GVH) reactions (Vos and Moore, 1974),
and the ability to mount delayed-type hypersesitivity (DTH) reactions
against oxazolone (Faith and Moore, 1977).
Organ weight effects, however, are a hallmark of TCDD exposure.
Thymic atrophy and decreased in cellularity are usually severe
(Chastain and Pazdernik, 1985; Moore and Faith, 1976) and have been
shown to be dose dependent (Fine et al. 1990; Vos and Moore, 1974).
Likewise, atrophy of the spleen, though not as sensitive to TCDD as the
thymus, has been shown to be dose dependent (Vos and Moore, 1974). An
increase in liver weight is routinely noticed following TCDD exposure.
This effect also, has been shown to be dose dependent by Kerkvliet et
al. (1990).
Effects on organ weights are suggestive of toxicity to that organ.
Thus, consistent thymic and splenic atrophy prompted research on the
immunotoxic effect of TCDD. Generally speaking, the mode through which
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TCDD exerts its immuntoxicity is unclear and there is disagreement
concerning the type of immunity most senstive to TCDD. Most
immunological parameters have been looked at and several have been
suggested as a target for TCDD toxicity. Vos and Moore (1974)
pinpointed the thymus as a target organ. Naturally, this suggests T-
cells and therefore cell-mediated immunity as targets for TCDD induced
toxicity. This is supported by Moore and Faith (1976) who found CMI
suppression in offspring of TCDD treated animals and claim CMI to be
more sensitive to TCDD toxicity than humoral immunity. Clark et al.
(1981) have reported suppression of CTL response as the most sensitive
indicator of toxicity; however, the doses they used are extremely low
and the results have never been duplicated. Chastain and Pazdernik
(1985) also claim CMI to be more sensitive than B-cell suppression upon
exposure to TCDD. Vecchi et al., (1980) reported no decrease in
ability to mount graft versus host (GVH) reactions.
The B-cell has also been suggested as the target lymphocyte for
TCDD toxicity. The antibody forming cell response, or plaque forming
cell (PFC) response is a standard assay for assessing humoral immunity
and is consistently suppressed in mice upon treatment with TCDD.
Suppression of this response in mice to both T-dependent and T-
independent antigens begins to appear at around 1.0 ug/kg (House et al.
1990; Vecchi et al. 1980, 1983; Davis and Safe, 1990).
Lymphoproliferation to mitogen stimulation is suppressed following in
utero exposure (Faith and Moore, 1977) but not in exposed adult mice
(Vecchi et al., 1980) . Using standard assays for T helper cell
population using mitogen stimulated cells, Dooley et al. (1990) found
no significant difference in tritiated thymidine uptake or in
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interleukin-2 production. They also found that TCDD treated T-cells
were not able to suppress naive splenocyte humoral response to the T-
dependent antigen, sheep red blood cells (SRBC) or the T-independent
antigen (DNP-Ficoll). Such results suggest the TCDD induced
alterations in T-cell function play no role in suppressing the antibody
response to antigen. Tucker et al. (1986) also noted that TCDD affects
the differentiation of B-cells into antibody secreting cells and thus
concluded the B-cells as target for TCDD.
TCDD suppression of innate immunity has been looked at by White et
al. (1986), who showed decreased levels of serum complement component
C3 at levels of TCDD as low as 0.5 ug/kg in B6D2F1 mice. No
significant difference in natural killer cell or macrophage function
has been obseved (House et al., 1990; Mantovanni, 1980) . Some
alterations in host resistance observed are increased suseptibiblity to
Streptococcus pneumonia (White,1986) and increased mortality due to
Influenza virus (House et al. 1990) and Herpes Simplex II virus (Clark
et al. 1983) . No increase in mortality due to Listeria monocytogenes
following TCDD exposure was found by House et al. (1990) .
Increase in liver weight is indicative of TCDD-induced
hepatotoxicity. TCDD exposure results in enzyme induction such as aryl
hydrocarbon hydrolase (AHH) (Tucker et al., 1986). A variey of enzymes
are temporarily induced by TCDD including Cytochrome P-450
(monooxygenase), glutathione-s-transferase, UDP-glucuronyltransferase,
and choline kinase (Neal, 1985) . Many compounds able to induce AHH are
also immunosuppressive (Tucker et al., 1986) and induction of AHH has
been shown to correlate with the toxicity of TCDD and other halogenated
aromatic hydrocarbon (HAH) congeners (Vecchi et al., 1983). The
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correlation between toxicity and enzyme induction is mediated by the Ah
receptor, which has a high binding affinity for TCDD and similar HAH's.
Low binding affinity correlates with reduced sensitivity to TCDD
toxicity (Clark et al., 1983).
The Ah locus codes for the Ah receptor. Strains of mice that
differ at the Ah locus also differ in their response to TCDD. For
example, C57B1/6 mice (Ah'^), because of their sensitivity to TCDD have
been designated Ah-responsive while DBA/2 mice (Ah'^) are more resistant
and designated Ah-nonresponsive. Studies suggest that TCDD toxicity
segregates with the Ah locus (Tucker et al., 1986) including
suppression of the PFC response (Davis and Safe, 1990) and CTL
suppression (Clark et al., 1983). Kervliet et al. (1990) looked at
C57B1/6 mice congenic at the Ah locus (Ah'^^ and Ah^^) to incontestibly
demonstrate that sensitivity to TCDD correlates with the Ah locus and
not with other differences between strains. The CTL response was
suppressed in both strains at lOug TCDD/kg and 20ug TCDD/kg, however
suppression in the Ah^^ was significantly and dramatically greater.
The same held true for reduction in thymus weight. Also, compared in
this study were three hexachlorobiphenyl (HxCB) congeners of known
affinity (high, intermediate, and low) for the Ah receptor. CTL
response, thymic weight reduction and corticosteroid induction
correlated with the affinity of the compounds.
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IV. The assays
The ^ ͣ' ͣCr release assay is a classic quantitation of lytic
capability (Henney, 1971; Brunner, 1968) . Therefore, it lends itself
well to the study of CTL and the effect of chemical exposure on their
fidelity. The assay relies on sensitized CTL recognizing and
effectively lysing labelled target cells. Lymphocytes are sensitized
with foreign (i.e., allogeneic) cells in vivo or lymphocytes in vitro.
The splenic lymphocytes or effector cells are then plated against the
original tumor (or target) cells labelled with ^-'-Cr. Viable CTL lyse
the target cells, releasing ^^Cr into the supernatant, which is
collected and quantified as a measure of cytotoxic efficiency. It is
important to note that the assay measures lytic activity of populations
of cells; it does not enumerate the number of cytotoxic cells in a
given population (Nabholz and MacDonald, 1983). Generally, the
following relationship is considered for conversion of raw counts to a
relative percent release scale:
(E-S)/(T-S) X 100%
where
E= release from spleen and target cells
S = spontaneous release (targets only)
T = maximum release (targets + 1% Triton-X)
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The plaque-forming cell (PFC) assay is widely used to assess
antibody formation at the cellular level (Barrett, 1988). Splenocytes
are plated in nutrient agar containing erythrocytes of the type used
during prior immunization. PFC quickly secrete antibody against
erythrocytes, which subsequently become coated with the antibody. The
additon of serum complement to the medium promotes the lysis of the red
blood cells, leaving behind a clear sphere, or plaque around an
antibody forming lymphocyte. The plaques are enumerated as a measure
of immunological capability.
The PFC assay obviously evaluates humoral immunity. However, the
immunosuppressive activity of TCDD has been well studied in this
laboratory using the PFC assay. Therefore, it was employed in this





C57BL/6J adult female mice from Jackson Laboratories, Bar Harbor,
ME, were employed throughout this study. The animals were housed 6-10
per cage containing heat-treated pine shavings (Beta Chips, North
Eastern Products Inc., Warrensberg, NY) in a controlled environment
room with a 12 hour light/dark cycle at an ambient temperature of 22+°C
and 50+5% relative humidity. They were allowed food (Purina Lab Chow,
Ralston Purina Co., St. Louis, MO) and water ad libitum.
Cell lines
The P-815 mastocytoma cell line was carried both in sterile tissue
culture and by weekly serial passage by ascites in DBA/2J adult female
mice (Jackson Laboratories, Bar Harbor, ME) housed as described above.
P-815 cells in tissue culture were maintained in RPMI-1640 media
supplemented with 10% heat-inactivated fetal calf serum (FCS), 25mM
HEPES, and 1% penicillin-streptomycin. Sterile Costar 50 ml tissue
culture flasks (Cambridge, MA) were seeded twice weekly and incubated
at 370c, 5% CO2.
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Chemical Exposure
TCDD (Radian Corporation, Austin, TX) was dissolved in acetone and
subsequently diluted in corn oil. The C57BL/6J mice were given either
a single intraperitoneal (ip) dose, at a dose rate of lOml/kg or dosed
weekly for four weeks. Control animals were given corn oil alone.
Sensitization
Spleen cells were allo-sensitized to either P-815 cells or DBA/2J
spleen cells (both H-2^) one week following the final TCDD dose either
by in vivo or in vitro method. For in vivo sensitization, the animals
were immunized, ip, with 2x10"^ P-815 cells (suspended in approximately
3 ml RPMI-1640 media). The mice were allowed to mount an immune
response for 10-11 days, after which the spleens were removed for the
assay.
To sensitize spleen cells in vitro, a mixed lymphocyte reaction
(MLR) was established. When two histoincompatible lymphocyte
populations are co-cultured, T-cell proliferation and CTL
differentiation ensue (Henney and Gillis, 1984). Usually, a one-way
reaction is engaged, wherein the proliferation of one cell type is
prevented. Here, DBA/2J spleen cells were irradiated at 2000 rad using
a Cesium source (National Institute of Environmental Health Sciences,
RTF, NC) to render them incapable of replication. Spleens were
asjSeptically removed and a single cell suspension prepared using a
Stomacher Lab-Blender (80) (Tekmar, Cinncinnati, OH) and Seward Medical
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Stomacher sterile bags. All in vitro MLR experiments were carried out
in RPMI-1640 media supplemented with 10% FBS, 25 mM HEPES, 0.1%
gentamycin and 5x10"^ M 2-mercaptoethanol. Cell counts were taken on a
Coulter Counter Model ZBI (Coulter Electronic Inc., Hialeah, FL) and
viabilities determined using the trypan blue exclusion method. The
C57BL/6J spleen cells were plated as responder cells (R) in a one way
MLR against the stimulator (S) irradiated DBA/2J spleen cells at R:S
ratios = 50:1 or 20:1 depending on cell yield. The Costar 6-well
plates were incubated at 37°C, 5% CO2 for 5 days.
For the PFC assay, mice were immunized, intraven^ously (iv), with
0.2ml of 5% SRBC four days prior to removal of spleen for assay.
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VI. METHODS
For the ^Icr assay, P-815 cells were collected from ascites, using
RPMI-1640 media + 25mM HEPES and centrifuged at 250 x g for 7 minutes.
After counts and viabilities were determined, three times the
calculated number of cells needed for labelling were aliquoted. ^-' ͣCr
at lOmCi/ml was added at lOul/lxlO^ cells and incubated for one hour.
Cells were then centrifuged and washed three times in assay media. For
the purpose of lowering background counts as much as possible, the
cells were resuspended and incubated for another hour. Following
incubation, the cells were centrifuged, resuspended in assay medium,
counted using a hemacytometer and resuspended to a final concentration
(1x10^ cells/ml in vivo, 2x10^ cells/ml in vitro).
Spleen cells were either collected from the 6-well plates or taken
from the sensitized animals and processed as described above. Media
for the ^•' ͣCr assay consisted of RPMI-1640 supplemented with 10%FBS,
25mM HEPES, and 0.1% gentaraycin. Final concentrations for cell
suspensions equal to IxlO"^ ml in vivo, 4x10^ ml in vitro. In 96-well
U bottomed tissue culture plates (Costar, Cambridge, MA), spleen cells
were plated as effector cells (E) against 51cr labelled P-815 target
cells (T) at E:T ratios = 100, 50, 25, 12.5:1 in vivo and 20, 10, 5,
2.5:1 in vitro. Plates were centrifuged at 250 x g for 5 minutes and
placed in a 37°C, 5%C02 incubator for four hours. After incubation
plates were removed and centrifuged a second time, the supernatant was
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collected using Skatron macrowell filters (Skatron, Inc.,Sterling, VA).
The amount of radioactivity in the supernatant fraction was determined
using a Packard Multi-Prias gamma counter (Packard Instrument Co.,
Downers Grove, XL).
For the PFC assay, the spleens from immunized animals were removed
and processed as described above using RPMI-1640 media supplemented
with 5% PCS and 0.1% gentamycin. The single cell suspension was
allowed to settle for 10 minutes and then passed through a type II,
class 2, cheese cloth filter (The Kendall Company, Boston, MA) to
remove debris. Dilutions of the suspension were made in media at 1:20
and 1:40. Sample cell counts were determined as described above.
SRBC (Environmental Diagnostics, Inc., Burlington, NC) were washed
three times with saline and resuspended to 40%. Reconstitued guinea
pig complement (Gibco, Grand Island, NY), previously absorbed with one
drop of washed SRBC and frozen, was thawed and diluted 1:3 with assay
media. Agar was prepared using 0.5% Bacto-Agar (Difco, Detroit, MI)
and 0.05% diethyl aminoethyl cellulose (DEAE-dextran, Pharmacia Fine
Chemicals, Uppsala, Sweden) in Earles's balanced salt solution (EBS).
The agar was dissolved in EBS in a boiling water bath, DEAE was then
added and the agar solution was maintained at 47°C in a constant
temperature water bath.
The spleen cells, agar, SRBC, and complement (20%, 5%, 70%, and 5%,
respectively) were added to 10 x 75 mm glass tubes in duplicate. The
solutions were vortexed briefly and poured into 100 mm petri plates
(Costar, Cambridge, MA) and covered with 45 x 50 mm glass cover slips
(Erie Scientific, Portmouth, NH). The agar was allowed to solidify
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(approximately 20 minutes) and the plates incubated at 37°C, 5% CO2 for
three hours, after which the plaques were eniomerated.
Dexamethasone 21-phosphate (DEX) is a well-known immunosuppressant
and was used for CTL positive control experiments. DEX (Sigma, St.
Louis, MO) solutions were prepared in an aqueous medium. Animals were
dosed by oral gavage for five consecutive days prior to euthanasia for
a final dose of 50 mg/kg for the in vitro sensitization or for 10
consecutive days following in vivo immunization for a final dose of 50
mg/kg. Euthanasia, removal and processing of spleen cells, and the
^^Cr release assay were performed for both in vivo and in vitro CTL
experiments as described above.
All data were analyzed using Dunnett's multiple comparison t-test
(Dunnett, 1955) with a p<0.05 considered significant.
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VII. RESULTS AND DISCUSSION
Exposure to TCDD had no effect on CTL generation at any dose in
this study. Single and weekly exposure results were compared, taking
into account weekly metabolism of TCDD (using a biological half life
for TCDD of 12 days). A single dose of 7.20, 2.40, 0.72, or 0.24 ]ag
TCDD/kg had no significant effect versus controls on either in vivo or
in vitro generated CTL response at any E:T ratio (see figures 1 and 2).
Likewise, four weekly exposures to TCDD did not significantly €iffect
the CTL response versus contols at levels equal to 3.0, 1.0, 0.30, and
0.10 ]ig  TCDD/kg/week or 0.30, 0.10, 0.03, and 0.01 ug/kg/week (see
figures 3-6) . Due to the amount of scatter in the data, the in vitro
generated CTL experiment following four weekly exposuresd to TCDD at
the higher dose level of 0.1 - 3.0 jig/kg/week was repeated. The
quality of the data improved while there was no change in CTL response
(see figure 7).
Organ weight effects were observed, as expected. Liver weight was
significantly increased and thymus weight decreased at TCDD doses of
3.0 and 1.0 yg/kg/week. Liver to body weight ratios were increased at
doses from 0.10 to 3.0 ug TCDD/kg/week; thymus to body weight ratio was
decreased at 3.0 pg TCDD/kg/week (see figure 8). This weight effect was
not evident when the experiment was repeated as mentioned above (as in
figure 7); here no weight effects were detected. No weight changes were
observed in the liver, spleen or thymus of mice dosed for four weeks at
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or below 0.30 ug/kg/week (see figure 9). A single dose of 7.20 or 2.40
pg TCDD/kg resulted in an increased liver to body weight ratio but no
alterations in spleen or thymus weights were observed (see figure 10).
The positive control experiments using DEX were successful; the CTL
assay response was shown to be indicative of immunosuppression. Both
in vivo and in vitro generated CTL responses were significantly lower
than controls (see figures 11 and 12).
As noted earlier, TCDD is expected to suppress the PFC response
beginning at around 1.0 ug/kg. Both the number of PFC per spleen and
PFC per 1x10^ cells were significantly decreased in mice dosed for four
weeks at 3.0 and 1.0 ug TCDD/kg/week (see figures 13 and 14).
The results of this study do not agree with the previously
published data of Clark et_al. (1981). They demonstrated suppression
of in vivo generated CTL responses following four weekly TCDD doses of
40, 4.0, and 0.4 yg/kg. The in vitro generated CTL was suppressed in
their lab at four weekly doses of 0.4, 0.04, and 0.004 yg/kg (400, 40,
and 4 ng/kg). The data presented here suggest that CTL function is not
affected at doses of TCDD upto 3.0 ug/kg/week.
The lytic unit, defined by Bryant et al., (1992) as the number of
effector cells required to lyse a specified percentage of target cells,
has become the primary method expressing CTL lytic activity.
Differences in lytic activity across a range of E:T ratios are most
often not constant; the lytic unit, therefore, provides some means for
standardizing percent specific lysis. Usually, the reference lysis
level is 20% and the results reported as lytic units per a specified
number of effector cells, often Ixio'' cells (Bryant et al., 1992).
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Clark et al. (1981) reported their data in terms of lytic units;
the reference lysis percentage used was 50%. To determine if massaging
the data could in some way help account for their results, the CTL data
presented here was converted to lytic units and analyzed, using a
computer program written for Clinical Immunolgy Services, Frederick,
MD. While the data in Fig. 15 suggest a dose-related decrease in lytic
units with increasing TCDD dose, TCDD dosed mice did not have
significantly reduced CTL activity. Furthermore, no significant
difference was found in the number of lytic units required to lyse 20%
of the target population in the other in vivo or the in vitro generated
assays (see figures 16-18).
There exists an inherent problem in attempting to prove data false.
Unfortunately, exact replication of Clark et al.'s 1981 work was an
impossibility. For example, Clark et al. (1981) used male C57B1/6J
mice for their study. Female mice of the same strain were used here,
as they are more easily housed together due to their lack of fighting
behavior. Though aggressive behavior may alter immune responses
through stress-induced immunosuppression and thereby influence the
immune response to chemical exposure, it is unlikely that sex
differences would account for such a large discrepancy as found here.
Also, Clark reported maximal response to alloantigen administered in
vivo at around six days. This defies expected immunologic kinetics for
the generation of CTL response. The response typically peaks at 10-12
days following viable tumor injection. For this reason, the CTL
response against both viable and non-viable P-815 cells was evaluated
at six days and at eleven days (see figures 19 and 20). Very poor
responses were mounted against either viable or non-viable tumor cells,
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administered ip, at six days. A strong response, however, was mounted
against only viable tumor cells at eleven days. This time difference
could be implicated in the vastly different results of the two studies.
Finally, Clark et al. found that thymocytes from treated animals could
significantly suppress the CTL activity of both naive and treated
splenocytes in culture. Addition of treated thymocytes to in vitro
cultures could help account for the exquisite sensitivity demonstrated
only in Clark's work.
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VIII. Table 1.
LD5O for Different Species
Species      LD^n(ug/kg) Reference
guinea pig 2 Neal(1985)
monkey 50 a
adult rat 60 »
weanling rat 25 ͣͣ ͣ »
dog 100 Tschirley(1986)
C57B1/6 mouse 132 Neal(1985)
DBA/2 mouse 620 H

















Fig. 1 THE EFFECT OF TCDD ON In vivo GENERATED







































Fig 2. THE EFFECT OF TCDD ON In vitro GENERATED
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Fig. 4 THE EFFECT OF 4 WEEKLY EXPOSURES TO TCDD ON
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Fig. 5 THE EFFECT OF 4 WEEKLY EXPOSURES TO TCDD ON
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Fig. 7 THE EFFECT OF 4 WEEKLY EXPOSURES TO TCDD ON
In vitro GENERATED CYTOTOXIC T LYMPHOCYTE ACTIVITY
100
czn Com on
ͣH 0.10 jug TCOO/kg/wkC:3 0.30 fxg TCDD/kg/wkE2g 1.00/ig TCDD/kg/wkCZ] 3.00 jug TCDD/kg/wk
2.5:1
EFFECTOR TO TARGET CELL RATIO(E:T)
Fig. 8 THE EFFECT OF 4 WEEKLY EXPOSURES































Fig. 9 THE EFFECT OF 4 WEEKLY EXPOSURES
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Fig. 10 THE EFFECT OF A SINGLE EXPOSURE
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Fig. 13 THE EFFECT OF TCDD ON THE PFC








Fig. 14 THE EFFECT OF TCDD ON THE PFC













Ffg. 15 THE EFFECT OF TCDD ON LYTIC UNITS PER 10^ CELLS
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Fig. 17 THE EFFECT OF TCDD ON LYTIC UNITS PER 10^ CELLS
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